{"id":"ic51","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IC51 is a recombinant HPV vaccine candidate designed to provide therapeutic benefit in patients with existing HPV-related disease, particularly cervical intraepithelial neoplasia (CIN). Unlike prophylactic HPV vaccines, IC51 aims to generate cellular and humoral immune responses against HPV-infected cells to promote clearance of infection and regression of precancerous lesions.","oneSentence":"IC51 is a therapeutic vaccine that stimulates the immune system to recognize and attack cells infected with human papillomavirus (HPV).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:12.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV infection"}]},"trialDetails":[{"nctId":"NCT00594958","phase":"PHASE3","title":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2006-09","conditions":"Japanese Encephalitis","enrollment":639},{"nctId":"NCT00605085","phase":"PHASE3","title":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":2675},{"nctId":"NCT00604708","phase":"PHASE3","title":"Immunogenicity Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":867},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT01047839","phase":"PHASE3","title":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-01","conditions":"Encephalitis","enrollment":100},{"nctId":"NCT01246479","phase":"PHASE3","title":"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-10","conditions":"Japanese Encephalitis","enrollment":23},{"nctId":"NCT00776230","phase":"PHASE3","title":"Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2008-09","conditions":"Japanese Encephalitis","enrollment":304},{"nctId":"NCT01296360","phase":"PHASE3","title":"Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-12","conditions":"Japanese Encephalitis","enrollment":300},{"nctId":"NCT00596102","phase":"","title":"Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":3258},{"nctId":"NCT00595309","phase":"PHASE3","title":"Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2007-12","conditions":"Japanese Encephalitis","enrollment":198},{"nctId":"NCT00595465","phase":"PHASE3","title":"Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2007-12","conditions":"Japanese Encephalitis","enrollment":389},{"nctId":"NCT00596271","phase":"PHASE3","title":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":192},{"nctId":"NCT00595790","phase":"PHASE3","title":"Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":374},{"nctId":"NCT00595270","phase":"PHASE3","title":"Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":349},{"nctId":"NCT01158599","phase":"PHASE4","title":"This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-06","conditions":"Japanese Encephalitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Japanese Encephalitis purified inactivated vaccine","Japanese Encephalitis vaccine"],"phase":"phase_3","status":"active","brandName":"IC51","genericName":"IC51","companyName":"Valneva Austria GmbH","companyId":"valneva-austria-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"IC51 is a therapeutic vaccine that stimulates the immune system to recognize and attack cells infected with human papillomavirus (HPV). Used for Cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}